Metastatic Solid Tumors

Oncology·MeSH: Colorectal Neoplasms

60 drugs in development·35 companies·11 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
pedmark	FENNEC PHARMACEUTICALS INC. (FENC)

Phase 3(13)

Drug	Company
Cetuximab	BeOne Medicines Ltd. (ONC)
ERAS-0015 in combination	Erasca, Inc. (ERAS)
ERAS-4001 in combination	Erasca, Inc. (ERAS)
Lazertinib	ENANTA PHARMACEUTICALS INC (ENTA)
MK-0472	Merck & Co., Inc. (MRK)
MK-1084	Merck & Co., Inc. (MRK)
Naporafenib	Erasca, Inc. (ERAS)
surzebiclimab	BeOne Medicines Ltd. (ONC)
tak-188	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-188	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-981	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-981	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
Trametinib	Erasca, Inc. (ERAS)

Phase 2(6)

Drug	Company
Amivantamab	ENANTA PHARMACEUTICALS INC (ENTA)
BGB-53038	BeOne Medicines Ltd. (ONC)
Direct Oral Anticoagulant	Structure Therapeutics Inc. (GPCR)
iph4502	Innate Pharma S.A. (IPHA)
pc14586	PMV Pharmaceuticals, Inc. (PMVP)
Pemetrexed	Structure Therapeutics Inc. (GPCR)

Phase 1(31)

Drug	Company
amg 410	AMGEN INC (AMGN)
amg 510	AMGEN INC (AMGN)
BGB-53038	ENANTA PHARMACEUTICALS INC (ENTA)
BGB-B455	Merus N.V. (MRUS)
CB-708 (ATG-037)	Calithera Biosciences, Inc. (CALA)
day301	Day One Biopharmaceuticals, Inc. (DAWN)
EO-3021	Elevation Oncology, Inc. (ELEV)
ERAS-0015	Erasca, Inc. (ERAS)
ERAS-007	Erasca, Inc. (ERAS)
ERAS-12	Erasca, Inc. (ERAS)
ERAS-3490	Erasca, Inc. (ERAS)
ERAS-4	Erasca, Inc. (ERAS)
ERAS-4001	Erasca, Inc. (ERAS)
ERAS-601	Erasca, Inc. (ERAS)
etigilimab	OncoMed Pharmaceuticals Inc (OMED)
hro761	NOVARTIS AG (NVSEF)
hro761	Novartis AG (NVS)
IDE-161	IDEAYA Biosciences, Inc. (IDYA)
MRG007	ArriVent BioPharma, Inc. (AVBP)
ngm438	NGM BIOPHARMACEUTICALS INC (NGM)
ngm831	NGM BIOPHARMACEUTICALS INC (NGM)
ST101	Royalty Pharma plc (RPRX)
ST101	PTC THERAPEUTICS, INC. (PTCT)
ST101	Myovant Sciences Ltd. (MYOV)
ST101	Janux Therapeutics, Inc. (JANX)
ST101	Merus N.V. (MRUS)
TAK-188	Merus N.V. (MRUS)
Temozolomide	Janux Therapeutics, Inc. (JANX)
Temozolomide	Myovant Sciences Ltd. (MYOV)
Temozolomide	Royalty Pharma plc (RPRX)
XB010	EXELIXIS, INC. (EXEL)

Preclinical(3)

Drug	Company
BP1003	BIO-PATH HOLDINGS, INC. (BPTH)
CLD-400 (RTNova)	Calidi Biotherapeutics Inc. (CLDI)
iv rhdnase i	Xenetic Biosciences, Inc. (XBIO)

BLA Filed(1)

Drug	Company
larotrectinib	LOXO ONCOLOGY, INC. (LOXO)

Phase 1/Phase 2(5)

Drug	Company
cr-001	CRESCENT BIOPHARMA, INC. (CBIO)
dcc-3116	Deciphera Pharmaceuticals, Inc. (DCPH)
iph4502	Innate Pharma SA (IPHYF)
nc762	NextCure, Inc. (NXTC)
wtx-330	Werewolf Therapeutics, Inc. (HOWL)

BioSniper tracks 60 drugs in development for Metastatic Solid Tumors across 35 companies.

There are 11 clinical trials targeting Metastatic Solid Tumors tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.